Business
Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today commented on the April 18, 2026 U.S. Executive Order, “Accelerating Medical Treatments for Serious Mental Illness,” which outlines federal actions intended to accelerate research, evidence generation, and a
About this update from Netramark Holdings Inc
[{"type":"image","alt":"NetraMark Holdings Inc.","displaySize":"","headline":null,"caption":"NetraMark Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/192769f9f65e10ea97c7137b2337b7be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cKmM3wfaRebYT3SszZY1sQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/192769f9f65e10ea97c7137b2337b7be","width":300,"height":94}},"lazy":false},{"type":"text","content":"TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today commented on the April 18, 2026 U.S. Executive Order, “Accelerating Medical Treatments for Serious Mental Illness,” which outlines federal actions intended to accelerate research, evidence generation, and appropriate regulatory pathways for certain investigational psychedelic drugs for serious mental illness, including programs involving ibogaine compounds.","length":653,"tagName":"p"},{"type":"text","content":"The Executive Order references several measures intended to support responsible development, including U.S. Food and Drug Administration (“FDA”) review prioritization mechanisms for psychedelic drugs that have received Breakthrough Therapy designation, and actions to expand evidence generation and clinical trial participation through collaboration among the United States Department of Health and Human Services (HHS), the FDA, and the Department of Veterans Affairs.","length":469,"tagName":"p"},{"type":"text","content":"NetraMark believes these developments underscore a broader shift in mental health drug development: accelerated interest in novel mechanisms must be matched by more rigorous and modern clinical trial design, particularly in central nervous system (CNS) indications where heterogeneity, expectancy effects, and placebo response can obscure true treatment effects.","length":362,"tagName":"p"},{"type":"text","content":"“Speed is important, but in regulatory science the real objective is credible evidence,” said Dr. Luca Pani, Chief Innovation and Regulatory Officer at NetraMark. “Psychedelic trials are amo...